Cargando…

Plasma leptin concentrations are greater in type II diabetic patients and stimulate monocyte chemotactic peptide-1 synthesis via the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway

BACKGROUND: Leptin is an adipokine that is recently reported to be a biomarker of systemic inflammation. Although atherosclerosis causes cardiovascular diseases, it is not clear whether leptin contributes to the acceleration of this process. In this study, we investigated whether alterations of plas...

Descripción completa

Detalles Bibliográficos
Autores principales: Cha, Jin Joo, Hyun, Young Youl, Jee, Yi Hwa, Lee, Mi Jin, Han, Kum Hyun, Kang, Young Sun, Han, Sang Youb, Cha, Dae Ryong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4716089/
https://www.ncbi.nlm.nih.gov/pubmed/26894024
http://dx.doi.org/10.1016/j.krcp.2012.06.004
_version_ 1782410497601044480
author Cha, Jin Joo
Hyun, Young Youl
Jee, Yi Hwa
Lee, Mi Jin
Han, Kum Hyun
Kang, Young Sun
Han, Sang Youb
Cha, Dae Ryong
author_facet Cha, Jin Joo
Hyun, Young Youl
Jee, Yi Hwa
Lee, Mi Jin
Han, Kum Hyun
Kang, Young Sun
Han, Sang Youb
Cha, Dae Ryong
author_sort Cha, Jin Joo
collection PubMed
description BACKGROUND: Leptin is an adipokine that is recently reported to be a biomarker of systemic inflammation. Although atherosclerosis causes cardiovascular diseases, it is not clear whether leptin contributes to the acceleration of this process. In this study, we investigated whether alterations of plasma leptin levels were related to diabetic nephropathy and systemic inflammation. In addition, we examined the physiologic action of leptin in cultured vascular smooth muscle cells (VSMCs). METHODS: A total of 126 type 2 diabetic participants and 37 healthy controls were studied. The diabetic participants were divided into three groups according to stage of nephropathy. We investigated whether leptin induced monocyte chemotactic peptide-1 (MCP-1) synthesis through the mitogen-activated protein kinase (MAPK) pathway using cultured VSMCs. RESULTS: Plasma leptin concentrations were significantly higher in the diabetic group than in the controls. Plasma leptin levels were positively correlated with body mass index, fasting and postprandial blood glucose, hemoglobin A1c, total cholesterol, urinary albumin excretion, high-sensitivity C-reactive protein (hsCRP), and MCP-1 plasma levels, and negatively correlated with creatinine clearance values. In cultured VSMCs, leptin increased MCP-1 production in a dose-dependent manner, and this stimulating effect of leptin on MCP-1 expression was reversed by the MAPK (MEK) inhibitor PD98059. In addition, leptin stimulated the phosphorylation of MEK, extracellular signal–regulated kinase, and E26-like transcription factor, which are components of the MAPK pathway. CONCLUSIONS: Overall, these findings suggest that activation of leptin synthesis may promote MCP-1 activation in a diabetic environment via the MAPK pathway in VSMCs and that it possibly contributes to the acceleration of atherosclerosis.
format Online
Article
Text
id pubmed-4716089
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-47160892016-02-18 Plasma leptin concentrations are greater in type II diabetic patients and stimulate monocyte chemotactic peptide-1 synthesis via the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway Cha, Jin Joo Hyun, Young Youl Jee, Yi Hwa Lee, Mi Jin Han, Kum Hyun Kang, Young Sun Han, Sang Youb Cha, Dae Ryong Kidney Res Clin Pract Original Article BACKGROUND: Leptin is an adipokine that is recently reported to be a biomarker of systemic inflammation. Although atherosclerosis causes cardiovascular diseases, it is not clear whether leptin contributes to the acceleration of this process. In this study, we investigated whether alterations of plasma leptin levels were related to diabetic nephropathy and systemic inflammation. In addition, we examined the physiologic action of leptin in cultured vascular smooth muscle cells (VSMCs). METHODS: A total of 126 type 2 diabetic participants and 37 healthy controls were studied. The diabetic participants were divided into three groups according to stage of nephropathy. We investigated whether leptin induced monocyte chemotactic peptide-1 (MCP-1) synthesis through the mitogen-activated protein kinase (MAPK) pathway using cultured VSMCs. RESULTS: Plasma leptin concentrations were significantly higher in the diabetic group than in the controls. Plasma leptin levels were positively correlated with body mass index, fasting and postprandial blood glucose, hemoglobin A1c, total cholesterol, urinary albumin excretion, high-sensitivity C-reactive protein (hsCRP), and MCP-1 plasma levels, and negatively correlated with creatinine clearance values. In cultured VSMCs, leptin increased MCP-1 production in a dose-dependent manner, and this stimulating effect of leptin on MCP-1 expression was reversed by the MAPK (MEK) inhibitor PD98059. In addition, leptin stimulated the phosphorylation of MEK, extracellular signal–regulated kinase, and E26-like transcription factor, which are components of the MAPK pathway. CONCLUSIONS: Overall, these findings suggest that activation of leptin synthesis may promote MCP-1 activation in a diabetic environment via the MAPK pathway in VSMCs and that it possibly contributes to the acceleration of atherosclerosis. Elsevier 2012-09 2012-06-26 /pmc/articles/PMC4716089/ /pubmed/26894024 http://dx.doi.org/10.1016/j.krcp.2012.06.004 Text en © 2012. The Korean Society of Nephrology. Published by Elsevier. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Cha, Jin Joo
Hyun, Young Youl
Jee, Yi Hwa
Lee, Mi Jin
Han, Kum Hyun
Kang, Young Sun
Han, Sang Youb
Cha, Dae Ryong
Plasma leptin concentrations are greater in type II diabetic patients and stimulate monocyte chemotactic peptide-1 synthesis via the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway
title Plasma leptin concentrations are greater in type II diabetic patients and stimulate monocyte chemotactic peptide-1 synthesis via the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway
title_full Plasma leptin concentrations are greater in type II diabetic patients and stimulate monocyte chemotactic peptide-1 synthesis via the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway
title_fullStr Plasma leptin concentrations are greater in type II diabetic patients and stimulate monocyte chemotactic peptide-1 synthesis via the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway
title_full_unstemmed Plasma leptin concentrations are greater in type II diabetic patients and stimulate monocyte chemotactic peptide-1 synthesis via the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway
title_short Plasma leptin concentrations are greater in type II diabetic patients and stimulate monocyte chemotactic peptide-1 synthesis via the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway
title_sort plasma leptin concentrations are greater in type ii diabetic patients and stimulate monocyte chemotactic peptide-1 synthesis via the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4716089/
https://www.ncbi.nlm.nih.gov/pubmed/26894024
http://dx.doi.org/10.1016/j.krcp.2012.06.004
work_keys_str_mv AT chajinjoo plasmaleptinconcentrationsaregreaterintypeiidiabeticpatientsandstimulatemonocytechemotacticpeptide1synthesisviathemitogenactivatedproteinkinaseextracellularsignalregulatedkinasepathway
AT hyunyoungyoul plasmaleptinconcentrationsaregreaterintypeiidiabeticpatientsandstimulatemonocytechemotacticpeptide1synthesisviathemitogenactivatedproteinkinaseextracellularsignalregulatedkinasepathway
AT jeeyihwa plasmaleptinconcentrationsaregreaterintypeiidiabeticpatientsandstimulatemonocytechemotacticpeptide1synthesisviathemitogenactivatedproteinkinaseextracellularsignalregulatedkinasepathway
AT leemijin plasmaleptinconcentrationsaregreaterintypeiidiabeticpatientsandstimulatemonocytechemotacticpeptide1synthesisviathemitogenactivatedproteinkinaseextracellularsignalregulatedkinasepathway
AT hankumhyun plasmaleptinconcentrationsaregreaterintypeiidiabeticpatientsandstimulatemonocytechemotacticpeptide1synthesisviathemitogenactivatedproteinkinaseextracellularsignalregulatedkinasepathway
AT kangyoungsun plasmaleptinconcentrationsaregreaterintypeiidiabeticpatientsandstimulatemonocytechemotacticpeptide1synthesisviathemitogenactivatedproteinkinaseextracellularsignalregulatedkinasepathway
AT hansangyoub plasmaleptinconcentrationsaregreaterintypeiidiabeticpatientsandstimulatemonocytechemotacticpeptide1synthesisviathemitogenactivatedproteinkinaseextracellularsignalregulatedkinasepathway
AT chadaeryong plasmaleptinconcentrationsaregreaterintypeiidiabeticpatientsandstimulatemonocytechemotacticpeptide1synthesisviathemitogenactivatedproteinkinaseextracellularsignalregulatedkinasepathway